Business
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
72-week data of atacicept in IgAN accepted as a best-ranked abstract Analysis of impact of atacicept on hematuria in IgAN accepted as a focused oral
About this update from Vera Therapeutics, Inc.
[{"type":"text","content":"72-week data of atacicept in IgAN accepted as a best-ranked abstract Analysis of impact of atacicept on hematuria in IgAN accepted as a focused oral presentation BRISBANE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced two presentations of data from the Phase 2b ORIGIN clinical trial of atacicept for the treatment of IgA nephropathy (IgAN) will be made at the 61st European Renal Association Congress (ERA24), which is taking place May 23—26, 2024, both virtually and in Stockholm. ERA24 Presentation Details: Free Communication Presentation – selected as a best-ranked abstract by the ERA24 Congress Paper Selection CommitteeTitle:Phase 2b ORIGIN Study Open Label Extension with Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria: Week 72 Interim AnalysisPresenting Author:Richard Lafayette, M.D., F.A.C.P., Professor of Medicine, Nephrology and Director of the Stanford Glomerular Disease Center at Stanford University Medical CenterSession:FC 17 - Novel treatments of immune mediated kidney diseasesRoom:A5Date, time:May 25, 2024, 15:36-15:48 CEST Focused Oral PresentationTitle:Impact of Atacicept on Hematuria in IgA Nephropathy: Post-Hoc Analysis of the Phase 2b ORIGIN StudyPresenting Author:Jürgen Floege, M.D., Senior Professor, Division of Nephrology and Rheumatology, University of Aachen, GermanySession:Glomerular, tubulo-interstitial diseases & general nephrologyRoom:Focused Oral Room 3Date, time:May 25, 2024, 12:00-13:15 CEST For more information on these abstracts, please visit the 61st ERA Congress website. About VeraVera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune disea...